Zufei Zhang

508 total citations
18 papers, 376 citations indexed

About

Zufei Zhang is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Zufei Zhang has authored 18 papers receiving a total of 376 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 11 papers in Molecular Medicine and 9 papers in Epidemiology. Recurrent topics in Zufei Zhang's work include Antibiotics Pharmacokinetics and Efficacy (11 papers), Antibiotic Resistance in Bacteria (11 papers) and Pneumonia and Respiratory Infections (9 papers). Zufei Zhang is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (11 papers), Antibiotic Resistance in Bacteria (11 papers) and Pneumonia and Respiratory Infections (9 papers). Zufei Zhang collaborates with scholars based in United States, Iran and United Kingdom. Zufei Zhang's co-authors include Jashvant D. Unadkat, Gabriela I. Patilea‐Vrana, Lu Gaohua, Matthew L. Rizk, Marjorie Z. Imperial, Elizabeth G. Rhee, Tian Zhao, Sheng Bi, Christopher Bruno and C.M. Chavez-Eng and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Zufei Zhang

18 papers receiving 371 citations

Peers

Countries citing papers authored by Zufei Zhang

Since Specialization

Citations

This map shows the geographic impact of Zufei Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zufei Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zufei Zhang more than expected).

Fields of papers citing papers by Zufei Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zufei Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zufei Zhang. The network helps show where Zufei Zhang may publish in the future.

Co-authorship network of co-authors of Zufei Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Zufei Zhang. A scholar is included among the top collaborators of Zufei Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zufei Zhang. Zufei Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Time‐varying brentuximab vedotin pharmacokinetics and weight‐based dosing in paediatric patients despite lower exposure in those aged 2 to <6 and 6–11 years 2024 ·British Journal of Clinical Pharmacology ·(unknown), Zufei Zhang, Anthony Lee, Keenan Fenton, (unknown), Amit Garg, Yen Lin Chia	2
2	Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma 2024 ·Clinical Cancer Research ·Zufei Zhang, (unknown), (unknown), Keenan Fenton, (unknown), (unknown), Joy Jiang, Sharon M. Castellino, Kara M. Kelly, Peter D. Cole, Frank G. Keller, Amit Garg, Yen Lin Chia	2
3	Abstract 6737: Exposure-response and age subgroup analyses to support body-weight (BW) dosing of brentuximab vedotin (BV) in newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults (aged 2-21 years [y]): A randomized children’s oncology group phase 3 trial (AHOD1331) 2023 ·Cancer Research ·Zufei Zhang, (unknown), (unknown), Keenan Fenton, (unknown), Shweta Jain, Joy Jiang, Sharon M. Castellino, Kara M. Kelly, Peter D. Cole, Frank G. Keller, Amit X. Garg, Yen Lin Chia	2
4	Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia 2022 ·The Journal of Clinical Pharmacology ·Wei Gao, Yogesh T. Patel, Zufei Zhang, Matthew G. Johnson, Jill Fiedler‐Kelly, Christopher Bruno, Elizabeth G. Rhee, Carisa De Anda, Hwa-ping Feng	6
5	Exposure–Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP 2022 ·Antimicrobial Agents and Chemotherapy ·Wei Gao, Julie Passarell, Yogesh T. Patel, Zufei Zhang, Gina Lin, Jill Fiedler‐Kelly, Christopher Bruno, Elizabeth G. Rhee, (unknown), Hwa-ping Feng	5
6	Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia and End‐Stage Renal Disease Receiving Intermittent Hemodialysis 2022 ·The Journal of Clinical Pharmacology ·Hwa-ping Feng, Yogesh T. Patel, Zufei Zhang, Jill Fiedler‐Kelly, Christopher Bruno, Elizabeth G. Rhee, Carisa De Anda, Wei Gao	2
7	Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial 2021 ·Critical Care ·Andrew F. Shorr, Christopher Bruno, Zufei Zhang, Erin Jensen, Wei Gao, (unknown), Jennifer A. Huntington, Brian Yu, Elizabeth G. Rhee, Carisa De Anda, Sumit Basu, Marin H. Kollef	15
8	Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population 2020 ·American Journal of Perinatology ·Jocelyn Y. Ang, Antonio Arrieta, John S. Bradley, Zufei Zhang, Brian Yu, Matthew L. Rizk, Matthew G. Johnson, Elizabeth G. Rhee	13
9	In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant Pseudomonas Aeruginosa 2020 ·Open Forum Infectious Diseases ·Donna Carr, Zufei Zhang, Qian Si, Fred Racine, Jing Chen Xiao, (unknown), Michael K. Wismer, Matthew G. Johnson, Hwa-ping Feng, Katherine Young, Matthew L. Rizk, Mary Motyl	3
10	Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP) 2020 ·Antimicrobial Agents and Chemotherapy ·Jennifer A. Huntington, Brian Yu, (unknown), Erin Jensen, Christopher Bruno, (unknown), Zufei Zhang, Wei Gao, Hwa-ping Feng, Elizabeth G. Rhee	7
11	Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia 2020 ·The Journal of Clinical Pharmacology ·Zufei Zhang, Yogesh T. Patel, Jill Fiedler‐Kelly, Hwa-ping Feng, Christopher Bruno, Wei Gao	20
12	Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis 2020 ·Pediatric Pulmonology ·Antonio Arrieta, Jocelyn Y. Ang, Zufei Zhang, Kajal Larson, Brian Yu, Matthew G. Johnson, Elizabeth G. Rhee, (unknown), Matthew L. Rizk	9
13	A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam 2019 ·International Journal of Infectious Diseases ·(unknown), Zufei Zhang, Fred Racine, Donna Carr, Jin Wu, Katherine Young, Matthew L. Rizk	35
14	Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects 2018 ·Antimicrobial Agents and Chemotherapy ·Matthew L. Rizk, Elizabeth G. Rhee, Patricia Jumes, Mark H. Gotfried, Tian Zhao, Eric Mangin, Sheng Bi, C.M. Chavez-Eng, Zufei Zhang, Joan R. Butterton	66
15	Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses 2017 ·Drug Metabolism and Disposition ·Zufei Zhang, Marjorie Z. Imperial, Gabriela I. Patilea‐Vrana, (unknown), Lu Gaohua, Jashvant D. Unadkat	82
16	Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the Model for Passive Placental Permeability Drugs 2017 ·Drug Metabolism and Disposition ·Zufei Zhang, Jashvant D. Unadkat	76
17	Prediction of Gestational Age–Dependent Induction of In Vivo Hepatic CYP3A Activity Based on HepaRG Cells and Human Hepatocytes 2015 ·Drug Metabolism and Disposition ·Zufei Zhang, Syed Muhammad Yousaf Farooq, Bhagwat Prasad, (unknown), Jashvant D. Unadkat	25
18	Effect of Salt Intake on Bioavailability of Mizoribine in Healthy Japanese Males 2012 ·Drug Metabolism and Pharmacokinetics ·Kazuya Ishida, (unknown), (unknown), Masato Taguchi, Toshio Miyawaki, H Matsukura, Osamu Uemura, Zufei Zhang, Jashvant D. Unadkat, Yukiya Hashimoto	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact